Jasmine Knoll
Clinical Genetics (M.D.) · Phoenix, AZNPI 1457745341
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Sanofi at 46.8% of the total.
Across 25 payments — averaging $41.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$487
- Takeda Pharmaceuticals U.S.A., Inc.$247
- Ultragenyx Pharmaceutical Inc.$136
- Biomarin Pharmaceutical Inc.$72
- Dexcom, Inc.$34
- Chiesi USA, Inc.$19
- plus $45 from 3 others
Across 154 payments — averaging $5947.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$278K
- Biomarin Pharmaceutical Inc.$262K
- Chiesi USA, Inc.$201K
- Sanofi US Services Inc.$101K
- Travere Therapeutics, Inc.$26K
- Sentynl Therapeutics, Inc.$19K
- plus $29K from 2 others
What the payments were for
- Food & beverage$93690%
- Education$10410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $487 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $247 |
| Ultragenyx Pharmaceutical Inc. | 5 | $136 |
| Biomarin Pharmaceutical Inc. | 3 | $72 |
| Dexcom, Inc. | 1 | $34 |
| Chiesi USA, Inc. | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $17 |
| Pfizer | 1 | $14 |
| Travere Therapeutics, Inc. | 3 | $14 |
How this compares
Too few clinical genetics (m.d.) providers in Arizonato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CarbagluCarglumic Acid | 11 | $2,730,973 |
| RavictiGlycerol Phenylbutyrate | 11 | $765,040 |
| FabrazymeAgalsidase Beta | 38 | $747,653 |
| CrysvitaBurosumab-Twza | 12 | $498,002 |
| GalafoldMigalastat Hcl | 14 | $426,104 |
| CerdelgaEliglustat Tartrate | 12 | $190,794 |
| JavygtorSapropterin Dihydrochloride | 21 | $124,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiFabrazyme, Cerdelga | $487 | $938,44750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical genetics (m.d.) providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Phoenix
- Kristin LindstromPhoenix$60K
- Rachel LombardoPhoenix$42K
- Theresa GrebePhoenix$4K
- John BakerPhoenix$580
- Christine UmandapPhoenix$230
- Derek NeilsonPhoenix$116
- Margaret PearsonScottsdale$212
- Radhika DhamijaScottsdale$14
- Mayowa OsundijiScottsdale$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.